INTRODUCTION: Aeromedical evacuation of @entity1 affected by severe @entity166 inside an aircraft transit isolator (ATI) system is at potential risk of @entity11535 ( @entity11535 ). A test flight was then conducted to quantify this risk during the transfer of an Ebola @entity1 from West Africa to Italy. CASE REPORT: A mannequin was inserted inside an ATI and instrumented to provide acceleration parameters throughout the test flight. The analysis of the data predicted a @entity11535 incidence of about 2% for a 6-h flight, so the decision to use anti- @entity11535 drugs only in selected cases was taken (i.e., those with positive past history of @entity11535 , @entity344 , or @entity11535 due to previous ambulance run). On this basis, an actual aeromedical evacuation of an Ebola @entity1 was successfully performed without the use of any anti- @entity11535 drugs. DISCUSSION: During aeromedical evacuation with ATI systems, the @entity1 's risk of @entity11535 should be evaluated on an individual basis and calibrated according to the specific exposure to motion evoked by the flight platform used. Due to the possible onset of untoward effects, prevention with anti- @entity11535 drugs in these @entity1 should be limited to selected cases. Lucertini M, Autore A, Covioli J, Biselli R, D'Amelio R. Motion sickness prediction in aeromedical evacuation of @entity1 with Ebola. Aerosp Med Hum Perform. 2016; 87(1):71-74.

Motion Sickness Prediction in Aeromedical Evacuation of XXXX with Ebola.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity11535 :: ('MESH:D009041', 'Disease') :: ['residual carsickness', 'motion sickness', 'MS'] @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious diseases'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal disorders']
@entity1 :: (9606,Species) :: ['Patients']
